Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Metadata

Authors/Creators:	Bygrave, CA Pawlyn, C Davies, FE Cairns, D https://orcid.org/0000-0002-2338-0179 Striha, A https://orcid.org/0000-0003-3363-8417 Hockaday, A Paterson, A Jones, JR Kishore, B Garg, M Williams, C Karunanithi, K Lindsay, J Jenner, MW Cook, G https://orcid.org/0000-0003-0223-3652 Drayson, MT Owen, RG Russel, NH Gregory, WM Morgan, GJ Jackson, G Kaiser, M
Dates:	Published: 29 November 2018
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User:	Symplectic Publications
Date Deposited:	17 Feb 2020 11:04
Last Modified:	29 Jun 2020 13:36
Status:	Published
Publisher:	American Society of Hematology
Identification Number:	https://doi.org/10.1182/blood-2018-99-111117
Related URLs:	Author

CORE (COnnecting REpositories)

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Metadata

Download not available

Export

Statistics